Skip to main content

Research Repository

Advanced Search

All Outputs (62)

Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus (2018)
Journal Article
Llibre, A., Shimakawa, Y., Mottez, E., Ainsworth, S., Buivan, T.-P., Firth, R., …Duffy, D. (2018). Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus. Gut, 67(11), 2017-2024. https://doi.org/10.1136/gutjnl-2017-315783

Objective: Recently approved direct acting antivirals provide transformative therapies for chronic hepatitis C virus (HCV) infection. The major clinical challenge remains to identify the undiagnosed patients worldwide, many of whom live in low-income... Read More about Development and clinical validation of the Genedrive point-of-care test for qualitative detection of hepatitis C virus.

Understanding hepatitis C intervention success: qualitative findings from the HepCATT study (2018)
Journal Article
Harris, M., Bonnington, O., Harrison, G., Hickman, M., & Irving, W. L. (in press). Understanding hepatitis C intervention success: qualitative findings from the HepCATT study. Journal of Viral Hepatitis, https://doi.org/10.1111/jvh.12869

The United Kingdom has committed to eliminating viral hepatitis as a public health threat. Innovative interventions for marginalized populations are required to realize this goal. In 2016, the HepCATT study team implemented a complex hepatitis C (HCV... Read More about Understanding hepatitis C intervention success: qualitative findings from the HepCATT study.

Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease (2018)
Journal Article
Kendall, T., Dolman, G., Duff, C., Paish, E. C., Zaitoun, A., Irving, W. L., Fallowfield, J. A., & Guha, I. N. (2018). Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease. Histopathology, 73(1), 90-100. https://doi.org/10.1111/his.13499

Aims. Needle biopsy remains essential for diagnosis in assessment of liver disease, although there remains associated risk. Examination is largely limited to subjective evaluation and biopsies are not exploited to provide personalised prognostic info... Read More about Hepatic elastin content is predictive of adverse outcome in advanced fibrotic liver disease.

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review (2018)
Journal Article
Walker, A. J., Peacock, C. J., Pedergnana, V., & Irving, W. L. (in press). Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review. Journal of Viral Hepatitis, 25(5), https://doi.org/10.1111/jvh.12871

Hepatitis C virus (HCV)-infected patients are at risk of developing hepatocellular carcinoma (HCC). Individuals at heightened riskcould be targeted by intensive follow-up surveillance. We have conducted a systematic review of the literature to identi... Read More about Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: a systematic review.

Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals (2017)
Journal Article
Simmons, R., Ireland, G., Irving, W., Hickman, M., Sabin, C., Ijaz, S., …Mandal, S. (in press). Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals. Journal of Viral Hepatitis, https://doi.org/10.1111/jvh.12844

Little is known about engagement and retention in care of people diagnosed with chronic hepatitis C (HCV) in England. Establishing a cascade of care informs targeted interventions for improving case-finding, referral, treatment uptake and retention i... Read More about Establishing the cascade of care for hepatitis C in England-benchmarking to monitor impact of direct acting antivirals.

Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis (2017)
Journal Article
Manouchehrinia, A., Tanasescu, R., Kareem, H., Jerca, O. P., Jabeen, F., Shafei, R., …Constantinescu, C. S. (in press). Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis. Journal of NeuroVirology, https://doi.org/10.1007/s13365-017-0569-1

Varicella zoster virus (VZV) infection has been implicated in multiple sclerosis (MS), but direct causal involvement has been disputed. Nevertheless, knowledge of VZV exposure is important, given the risk of serious complications of first exposure wh... Read More about Prevalence of a history of prior varicella/herpes zoster infection in multiple sclerosis.

MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C (2016)
Journal Article
International Liver Disease Genetics Consortium, Thabet, K., Asimakopoulos, A., Shojaei, M., Romero-Gomez, M., Mangia, A., …Eslam, M. (2016). MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Nature Communications, 7(1), Article 12757. https://doi.org/10.1038/ncomms12757

© 2016 The Author(s). Cirrhosis likely shares common pathophysiological pathways despite arising from a variety of liver diseases. A recent GWAS identified rs641738, a polymorphism in the MBOAT7 locus, as being associated with the development of alco... Read More about MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C.

Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article
Cheung, M. C., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., …Irving, W. L. (2016). Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 65(4), 741-747. https://doi.org/10.1016/j.jhep.2016.06.019

Direct-acting antivirals have become widely used for patients with chronic hepatitis C virus infection with decompensated cirrhosis. Virological responses are excellent and early improvements in liver function, at least in a proportion of patients, h... Read More about Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis.

Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis (2016)
Journal Article
Foster, G. R., Irving, W. L., Cheung, M. C., Walker, A. J., Hudson, B. E., Verma, S., McLauchlan, J., Mutimer, D. J., Brown, A., Gelson, W. T., MacDonald, D. C., & Agarwal, K. (2016). Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. Journal of Hepatology, 64(6), 1224-1231. https://doi.org/10.1016/j.jhep.2016.01.029

Background and Aims: All oral direct-acting antivirals (DAAs) effectively treat chronic hepatitis C virus (HCV) infection, but the benefits in advanced liver disease are unclear. We compared outcomes in treated and untreated patients with decompensat... Read More about Cohort study of the impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis.

Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment. (2016)
Journal Article

Background: Engagement of individuals infected with hepatitis C virus (HCV) with care pathways remains a major barrier to realizing the benefits of new and more effective antiviral therapies. After an exploratory study, we have undertaken an evidence... Read More about Clinical care pathways for patients with hepatitis C: reducing critical barriers to effective treatment..

Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. (2014)
Journal Article

Background & Aims: Noninvasive tests cannot differentiate between adjacent stages of fibrosis, which limits assessment of disease progression and regression during therapy. We investigated whether levels of cytokines and extracellular matrix proteins... Read More about Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C..

Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection (2014)
Journal Article
Lattimore, S., Irving, W. L., Collins, S., Penman, C., & Ramsay, M. (2014). Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection. Hepatology, 59(4), 1343-1350. https://doi.org/10.1002/hep.26926

The aim of this work was to develop and validate an algorithm to monitor rates of, and response to, treatment of patients infected with hepatitis C virus (HCV) across England using routine laboratory HCV RNA testing data. HCV testing activity between... Read More about Using surveillance data to determine treatment rates and outcomes for patients with chronic hepatitis C virus infection.

Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies (2014)
Journal Article
Edwards, V. C., McClure, P., Brown, R. J., Thompson, E., Irving, W. L., & Ball, J. K. (in press). Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies. Journal of General Virology, 95(1), https://doi.org/10.1099/vir.0.057828-0

Sequence analysis is used to define the molecular epidemiology and evolution of the hepatitis C virus. Whilst most studies have shown that individual patients harbour viruses that are derived from a limited number of highly related strains, some rece... Read More about Use of short-tandem repeat (STR) fingerprinting to validate sample origins in hepatitis C virus molecular epidemiology studies.

The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy (2013)
Journal Article
Backx, M., Lewszuk, A., White, J., Cole, J., Sreedharan, A., van Sanden, S., …Irving, W. L. (2014). The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy. Journal of Viral Hepatitis, 21(3), https://doi.org/10.1111/jvh.12132

Chronic hepatitis C virus (HCV) infection places a considerable economic burden on health services. Cost-effectiveness analyses of antiviral treatment for patients with chronic HCV infection are dependent on assumptions about cost reductions followin... Read More about The cost of treatment failure: resource use and costs incurred by hepatitis C virus genotype 1-infected patients who do or do not achieve sustained virological response to therapy.

Act now against new NHS competition regulations (2013)
Journal Article
Davis, J., Banks, I., Wrigley, D., Peedell, C., Pollock, A., McPherson, K., …Chandy, R. (2013). Act now against new NHS competition regulations. BMJ, 346, https://doi.org/10.1136/bmj.f1819

An open letter to the BMA and the Academy of Medical Royal Colleges calls on them to make a joint public statement of opposition to the amended section 75 regulations

Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial (2009)
Journal Article
Horwood, J., Clement, C., Roberts, K., Waldron, C., Irving, W., Macleod, J., & Hickman, M. (2009). Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial. Journal of Clinical Virology, 44(2), https://doi.org/10.3399/bjgp20x708785

Background Hepatitis C virus (HCV) infection is a key cause of liver disease but can be cured in more than 95% of patients. Around 70 000 people in England may have undiagnosed HCV infection and many more will not have been treated. Interventions to... Read More about Increasing uptake of hepatitis C virus infection case- finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial.

Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease (2008)
Journal Article
Hamed, M. R., Tarr, A. W., McClure, C. P., Ball, J. K., Hickling, T. P., & Irving, W. L. (2008). Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease. Journal of Viral Hepatitis, 15(5), 339-345. https://doi.org/10.1111/j.1365-2893.2007.00947.x

Hepatitis C virus (HCV) causes acute and chronic liver diseases in humans. Its two envelope glycoproteins, E1 and E2, provide a target for host immune recognition. HCV genotypes are classified into six genetic groups. To study the role of anti-HCV E1... Read More about Association of antibodies to hepatitis C virus glycoproteins 1 and 2 (anti-E1E2) with HCV disease.

Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33 (2007)
Journal Article
Tarr, A. W., Owsianka, A. M., Jayaraj, D., Brown, R. J., Hickling, T. P., Irving, W. L., …Ball, J. K. (2007). Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. Journal of General Virology, 88(11), 2991-3001. https://doi.org/10.1099/vir.0.83065-0

Hepatitis C virus (HCV) is a major cause of liver disease worldwide and there is a pressing need for the development of a preventative vaccine as well as new treatments. It was recently demonstrated that the mouse monoclonal antibody (mAb) AP33 poten... Read More about Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33.